---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-129882"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2022-12-23T23:59:59+00:00"
generated_at: "2026-06-20T23:23:29.871459+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics raises $25M in registered direct offering at $0.8784/share

## Summary
- Registered direct offering of 28,460,831 shares at $0.8784 per share for gross proceeds of ~$25M.
- Largest stockholder GMS Ventures participated in the offering.
- Net proceeds to support ONS-5010 development program and working capital; may include debt repayment.
- Offering expected to close December 28, 2022; M.S. Howells & Co. acted as placement agent.
- BTIG served as exclusive financial advisor to the company.

## SEC filing metadata
- accession: 0001104659-22-129882
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2022-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465922129882/0001104659-22-129882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465922129882/tm2233312d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-129882
- JSON: https://secwatch.observer/filing/0001104659-22-129882.json
- Plain text: https://secwatch.observer/filing/0001104659-22-129882.txt

## Key facts
- Material Agreements
  Outlook Therapeutics, Inc. entered into Engagement Letter with M.S. Howells & Co. (the “Placement Agent”) (effective 2022-12-22).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: M.S. Howells & Co. (the “Placement Agent”)
  - Effective: 2022-12-22
  source text: Pursuant to a letter agreement dated as of December 22, 2022 (the “Engagement Letter”), the Company engaged M.S. Howells & Co. (the “Placement Agent”) to act as placement agent with respect to certain accredited investors in the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465922129882/0001104659-22-129882-index.htm
- Material Agreements
  Outlook Therapeutics, Inc. entered into Purchase Agreements with certain institutional and accredited investors, including GMS Ventures and Investments, an affiliate of the Company valued at approximately $25 million (effective 2022-12-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors, including GMS Ventures and Investments, an affiliate of the Company
  - Value: approximately $25 million
  - Effective: 2022-12-23
  source text: On December 23, 2022, Outlook Therapeutics, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), including GMS Ventures and Investments, an affiliate of the Company, pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of 28,460,831 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $0.8784 per share, for aggregate gross proceeds to the Company of approximately $25 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465922129882/0001104659-22-129882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.